Myeloma Paper of the Day, September 8th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Retrospective case-control study with Korea National Health Insurance Service data covering ~50 million Koreans finds myeloma patients had higher risk of dementia with in 3 years of diagnosis, but lower after that (HR 0.625).”

Source: Robert Orlowski/X

Dementia Incidence in Survivors of Multiple Myeloma: A National Case-Control Study Conducted in Korea (The CAREMM-2106 Study)

Authors: Jeonghoon Ha, Suein Choi, Seulji Moon, Jinseon Han, Jeongyoon Lee2, Sung-Soo Park, Sheng-Min Wang, Seunghoon Han, Chang-Ki Min.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.